Summit Therapeutics Inc.SMMTNASDAQ

Revenue (LTM)

Net Income (LTM)

$-1.1B

-387.8% YoY

Free Cash Flow

$-324M

Revenue CAGR (5Y)

—

Marginsdeclining

FCF($0.3B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	2	1↓61.1%	0	0	0
Gross Profit	2	-2↓200.1%	-2↓13.3%	-15↓632.0%	-0↑99.3%
Operating Income	-86	-60↑30.8%	-90↓50.5%	0↑100.3%	-812↓259600.9%
Net Income	-89	-79↑11.1%	-615↓680.5%	-221↑64.0%	-1,080↓387.8%
EBITDA	-86	-73↑14.9%	-69↑5.0%	-213↓206.5%	-801↓276.4%
EPS Diluted	-0.96	-0.38↑60.4%	-0.99↓160.5%	-0.31↑68.7%	-1.44↓364.5%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	72	349↑385.6%	71↓79.5%	105↑46.8%	225↑114.8%
Total Current Assets	97	657↑574.9%	190↓71.1%	424↑123.4%	720↑70.0%
Total Assets	113	664↑485.8%	203↓69.4%	436↑114.6%	751↑72.5%
Total Current Liabilities	26	39↑51.4%	20↓47.4%	42↑104.5%	73↑74.9%
Total Liabilities	30	538↑1686.4%	125↓76.7%	47↓62.6%	92↑97.2%
Total Equity	83	127↑52.1%	78↓38.7%	389↑400.4%	659↑69.5%
Total Debt	3	519↑18547.1%	106↓79.5%	7↓93.2%	16↑114.8%
Net Debt	-69	170↑346.6%	35↓79.6%	-98↓381.6%	-210↓114.8%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-73	-42↑42.7%	-77↓84.6%	-142↓85.1%	-323↓127.2%
Capital Expenditure	-0	-1↓103.9%	-0↑79.5%	-0↓8.6%	-1↓372.7%
Free Cash Flow	-73	-42↑42.1%	-77↓82.2%	-142↓85.0%	-324↓127.5%
Stock-Based Comp	9	10↑4.4%	14↑42.7%	51↑261.4%	732↑1336.7%
Net Change in Cash	5	577↑10633.5%	-577↓200.1%	34↑105.8%	120↑256.6%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance